Background: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has tended to focus on improving outcomes, shortened treatment length and reduced side-effects of interferon-free regimens. How these treatments are being understood and experienced by the people receiving them has so far been overlooked. This study therefore aimed to explore the lived experience of individuals taking interferon-free HCV therapies. Methods: Data were generated through 16 semi-structured interviews with a purposive sample of eight participants, recruited from a university hospital in Scotland. The interviews took place between June 2015 and March 2016, before and after a period of interferon-free HCV treatment. The data were inter...
Hepatitis C virus (HCV) is a growing problem affecting thousands of people in the UK. The majority o...
Aim: The aim of the study was to explore the experiences of persons from marginalised/at-risk backgr...
The lived experience of both interferon-based and new interferon-free treatments in patients with he...
Background: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has ...
Aims and objectives To explore the experience of adults living with hepatitis C in a new era of inte...
BACKGROUND: The development of simplified and effective hepatitis C (HCV) pharmaceuticals enables tr...
BACKGROUND: Rapid advances in the treatment of the hepatitis C virus (HCV) have been witnessed in cl...
Abstract Background Millions of Americans are living with hepatitis C, the leading cause of liver di...
Background: Universal access to the hepatitis C direct acting antiviral (DAAs) regimens presents a u...
Aim. The purpose of the study was to explore the issues surrounding chronic hepatitis C, combination...
Among the estimated 210,000 Australians living with the hepatitis C virus, over 80% will go on to li...
Aim. The purpose of the study was to explore the issues surrounding chronic hepatitis C, combination...
Purpose Direct acting antiviral treatment to cure hepatitis C virus (HCV) is becoming more accessibl...
The aim of this study was to explore the experiences of hope people had after undergoing treatment f...
Direct-acting antivirals present a treatment opportunity that provides high rates of sustained viral...
Hepatitis C virus (HCV) is a growing problem affecting thousands of people in the UK. The majority o...
Aim: The aim of the study was to explore the experiences of persons from marginalised/at-risk backgr...
The lived experience of both interferon-based and new interferon-free treatments in patients with he...
Background: International discourse concerning the evolution in hepatitis C virus (HCV) therapy has ...
Aims and objectives To explore the experience of adults living with hepatitis C in a new era of inte...
BACKGROUND: The development of simplified and effective hepatitis C (HCV) pharmaceuticals enables tr...
BACKGROUND: Rapid advances in the treatment of the hepatitis C virus (HCV) have been witnessed in cl...
Abstract Background Millions of Americans are living with hepatitis C, the leading cause of liver di...
Background: Universal access to the hepatitis C direct acting antiviral (DAAs) regimens presents a u...
Aim. The purpose of the study was to explore the issues surrounding chronic hepatitis C, combination...
Among the estimated 210,000 Australians living with the hepatitis C virus, over 80% will go on to li...
Aim. The purpose of the study was to explore the issues surrounding chronic hepatitis C, combination...
Purpose Direct acting antiviral treatment to cure hepatitis C virus (HCV) is becoming more accessibl...
The aim of this study was to explore the experiences of hope people had after undergoing treatment f...
Direct-acting antivirals present a treatment opportunity that provides high rates of sustained viral...
Hepatitis C virus (HCV) is a growing problem affecting thousands of people in the UK. The majority o...
Aim: The aim of the study was to explore the experiences of persons from marginalised/at-risk backgr...
The lived experience of both interferon-based and new interferon-free treatments in patients with he...